前列腺癌细胞增强白细胞介素-15介导的自然杀伤细胞扩增
该研究将正常供者血淋巴细胞与前列腺癌细胞系或非癌细胞系共培养,并分别加入IL-2、IL-12、IL-15、IFN-γ或IL-21七天后检测NK细胞扩增。结果显示仅IL-15能在前列腺癌细胞存在时诱导NK、NKT和CD8 T细胞扩增,且癌细胞存在时NK细胞扩增比单独培养高至多50%。
要点
- 仅IL-15能在前列腺癌细胞存在时诱导NK、NKT和CD8 T细胞扩增。
- 前列腺癌细胞存在时NK细胞扩增比单独培养高至多50%。
- 非癌细胞系不引起NK细胞扩增,NKG2D阻断不抑制该扩增。
核心结论
- 在多种NK细胞激活细胞因子中,IL-15是唯一能在前列腺癌细胞存在时刺激NK细胞扩增的细胞因子,因此IL-15可能是未来前列腺癌瘤内治疗的良好候选。
研究设计与样本
- 研究将正常供者血淋巴细胞与前列腺癌细胞系或非癌细胞系共培养,并分别加入IL-2、IL-12、IL-15、IFN-γ或IL-21,培养7天。
- 通过流式细胞术检测NK细胞、NKT细胞和CD8 T细胞的扩增,并与无前列腺细胞时的扩增比较。
- 评估NK细胞的穿孔素和肿瘤细胞杀伤活性,分析NK细胞受体及其在前列腺肿瘤细胞上的相应配体。
- 研究肿瘤分泌的热休克蛋白HSP90和HSP70在共培养NK细胞扩增中的作用。
主要发现
- 在已知可导致NK细胞激活和扩增的细胞因子中,仅IL-15能在前列腺癌细胞系存在时主动诱导NK、NKT和CD8 T细胞扩增。
- 前列腺癌细胞(LNCaP、PC3)存在时NK细胞扩增远大于淋巴细胞单独孵育时,高至多50%。
- 非癌细胞系(PNT2和WPMY-1)不引起NK细胞扩增。
- NK细胞的溶细胞活性(以穿孔素、CD107a和肿瘤细胞杀伤衡量)在IL-15共培养中最高。
- 前列腺癌细胞存在时NKG2D上调程度大于单独IL-15时淋巴细胞的上调,但阻断NKG2D不抑制肿瘤细胞存在时NK细胞的增强扩增。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify cytokines that can activate and expand NK cells in the presence of prostate cancer cells in order to determine whether these agents may be useful in future intra-tumoural administration in pre-clinical and clinical prostate cancer trials. MATERIALS AND METHODS: Lymphocytes isolated from normal donor blood were set up in co-cultures with either cancer or non-cancerous prostate cell lines, together with each of the cytokines interleukin (IL)-2, IL-12, IL-15, interferon (IFN)-γ or IL-21 for a period of 7 days. Then, expansion of NK cells, NKT cells and CD8 T cells was measured by flow cytometry and compared with the expansion of the same cells in the absence of prostate cells. The cytotoxic activity of NK cells, as measured by perforin and tumour cell killing, was also assessed. NK cell receptors and their corresponding ligands on prostate tumour cells were analysed to determine whether any of these were modulated by co-culture. The role of the tumour-secreted heat shock proteins HSP90 and HSP70 in the expansion of NK cells in the co-cultures was also investigated because of their effects on NK and CD8 T-cell activation. RESULTS: We showed that, among a panel of cytokines known to cause NK cell activation and expansion, only IL-15 could actively induce expansion of NK, NKT and CD8 T cells in the presence of prostate cancer cell lines. Furthermore, the expansion of NK cells was far greater (up to 50% greater) in the presence of the cancer cells (LNCaP, PC3) than when lymphocytes were incubated alone. In contrast, non-cancerous cell lines (PNT2 and WPMY-1) did not exert any expansion of NK cells. The cytolytic activity of the NK cells, as measured by perforin, CD107a and killing of tumour cells, was also greatest in co-cultures with IL-15. Examination of NK cell receptors shows that NKG2D is upregulated to a greater degree in the presence of prostate cancer cells, compared with the upregulation with IL-15 in lymphocytes alone. However, blocking of NKG2D does not inhibit the enhanced expansion of NK cells in the presence of tumour cells. CONCLUSIONS: Among a panel of NK cell-activating cytokines, IL-15 was the only cytokine that could stimulate expansion of NK cells in the presence of prostate cancer cells; therefore IL-15 may be a good candidate for novel future intra-tumoural therapy of the disease.
引用
- Sakellariou C, Elhage O, Papaevangelou E, et al. Prostate cancer cells enhance interleukin-15-mediated expansion of NK cells. BJU Int. 2019. PMID: 31392791. doi:10.1111/bju.14893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。